Phentolamine Mesylate

PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026. The presentations will include data across various areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia; results from a Phase 1 study of varenicline solution nasal spray in healthy Japanese adults; and a post-hoc analysis of MIRA-2, a Phase 3 study evaluating the optical impact of RYZUMVI® for reversing pharmacologically-induced mydriasis. Additional data will include an encore presentation of LYNX-2, a Phase 3 study evaluating MR-142 (phentolamine ophthalmic solution 0.75%) for visual disturbances in low light conditions in post-refractive surgery patients. All accepted scientific abstracts are available on the ASCRS Annual Meeting website. Full List of Viatris Presentations at ASCRS Annual Meeting 2026: To complement its scientific program, and to further foster peer-to-peer exchange and support clinicians in the evolving management of presbyopia, Viatris provided an independent educational grant for the following educational symposium hosted by PRIME®, a nationally recognized continuing medical education platform: Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction Saturday, April 11 6–7:30 p.m. ET The Westin DC Downtown, River Birch Ballroom More information on the data presentations and symposium can be found on the ASCRS website here, and Viatris can be found at booth #233. All educational content of the ASCRS Annual Meeting is planned by its Program Committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services. Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights to Viatris to commercialize phentolamine ophthalmic solution 0.75% in the U.S. About Presbyopia Presbyopia is the gradual loss of near focusing ability due to aging, that typically becomes noticeable in the early to mid-40s. It is a nearly universal condition that, when uncorrected, contributes significantly to vision-related disability. Presbyopia leads to symptoms like eye strain and blurred near vision, impacting daily tasks and productivity. It affects nearly 128 million people in the United States—about 90% of adults over 45. By age 50, most Americans require some form of near-vision correction, such as reading glasses or multifocal lenses. Globally, an estimated 1.8 billion people were presbyopic in 2015, projected to rise to 2.1 billion by 2030. RYZUMVI® IMPORTANT SAFETY INFORMATION Warnings and Precautions Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis). Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface. Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses. Adverse Reactions The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%). Please see Full Prescribing Information About Mesopic Vision Mesopic vision is defined as vision in dim light (interface of bright light and night vision) conditions that leverages both rod and cone photoreceptors. Decreased low contrast visual acuity under mesopic conditions occurs when the pupil dilates in low-light conditions allowing peripheral unfocused rays of light to enter the eye. The total diagnosed prevalence of Night Vision Disturbance (NVD) across the 7 Major Markets (United States, United Kingdom, Germany, France, Italy, Spain, and Japan) was estimated to be nearly 55 million in 2023, with the U.S. representing approximately 45% of cases. The condition is particularly common in patients with increased ocular aberrations and ocular scatter from keratorefractive surgery (including Laser-Assisted In Situ Keratomileusis (LASIK), Photorefractive Keratectomy (PRK), Small-Incision Lenticule Extraction (SMILE), and Radial Keratotomy (RK)). It is estimated that approximately 800,000 refractive surgeries are performed in the U.S. each year, with 25% of patients suffering from visual aberrations (e.g., glare, halos, starburst) at 1-month. There are currently no FDA-approved treatments. About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X. Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements about presentations, study results, and licensing agreements. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; Viatris' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. SOURCE Viatris Inc. 21% more press release views with Request a Demo

Oral presentations feature phentolamine ophthalmic solution 0.75% RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026. The presentations will include data across key areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating phentolamine ophthalmic solution 0.75% for presbyopia, and a post-hoc analysis of MIRA-2, a Phase 3 study evaluating the optical impact of RYZUMVI® for reversing pharmacologically-induced mydriasis, and an encore presentation of results from LYNX-2, a Phase 3 study evaluating phentolamine ophthalmic solution 0.75% for visual disturbances in low light conditions in post-refractive surgery patients. Full List of Presentations at ASCRS Annual Meeting 2026 Abstract Abstract Details Abstract No. 123806 Optical Impact of Reversing Pharmacologically Induced Mydriasis on Image Quality Electronic Poster (On-Demand) Friday, April 10 Room: WEWCC Abstract No. 119626 Phentolamine Ophthalmic Solution Provides Durable Improvement in Distance Corrected Near Vision for Presbyopic Patients in a Phase 3 Study Oral Presentation Paper Session: Presbyopia Correction - Digital & Other Saturday, April 11 8:00–8:05 a.m. ET Room: WEWCC - Level 2, 209C Abstract No. 119714 Phase 3 Randomized Controlled Study of Phentolamine Ophthalmic Solution in Post-Refractive Surgery Patients with Impaired Mesopic Vision Oral Presentation Paper Session: Refractive Complications, Digital, & Other Saturday, April 11 8:20–8:25 a.m. ET Room: WEWCC - Level 2, 209A Opus’ partner Viatris has provided an independent grant for an educational symposium hosted by PRIME ® , a nationally recognized continuing medical education platform. The symposium, entitled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction”, is designed to complement its scientific program, further foster peer-to-peer exchange, and support clinicians in the evolving management of presbyopia. The event will take place on Saturday, April 11 from 6–7:30 p.m. ET at The Westin DC Downtown, River Birch Ballroom. More information on the data presentations and symposium can be found on the ASCRS website here . Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights to Viatris to commercialize phentolamine ophthalmic solution 0.75% in the U.S. About Presbyopia Presbyopia is the gradual loss of near focusing ability due to aging, that typically becomes noticeable in the early to mid-40s. It is a nearly universal condition that, when uncorrected, contributes significantly to vision-related disability. Presbyopia leads to symptoms like eye strain and blurred near vision, impacting daily tasks and productivity. It affects nearly 128 million people in the United States—about 90% of adults over 45. By age 50, most Americans require some form of near-vision correction, such as reading glasses or multifocal lenses. Globally, an estimated 1.8 billion people were presbyopic in 2015, and this number is projected to rise to 2.1 billion by 2030. About Mesopic Vision Mesopic vision is defined as vision in dim light (interface of bright light and night vision) conditions that leverages both rod and cone photoreceptors. Decreased low contrast visual acuity under mesopic conditions occurs when the pupil dilates in low-light conditions allowing peripheral unfocused rays of light to enter the eye. The total diagnosed prevalence of Night Vision Disturbance (NVD) across the 7 Major Markets (United States, United Kingdom, Germany, France, Italy, Spain, and Japan) was estimated to be nearly 55 million in 2023, with the U.S. representing approximately 45% of cases. The condition is particularly common in patients with increased ocular aberrations and ocular scatter from keratorefractive surgery (including Laser-Assisted In Situ Keratomileusis (LASIK), Photorefractive Keratectomy (PRK), Small-Incision Lenticule Extraction (SMILE), and Radial Keratotomy (RK)). It is estimated that approximately 800,000 refractive surgeries are performed in the U.S. each year, with 25% of patients suffering from visual aberrations (e.g., glare, halos, starburst) at 1-month. There are currently no FDA-approved treatments. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution 0.75%, beyond its approved use for pharmacologically induced mydriasis, with a supplemental new drug application under review for presbyopia and an ongoing Phase 3 pivotal trial for mesopic, low contrast conditions after keratorefractive surgery (dim light disturbances). The Company is based in Research Triangle Park, NC. For more information, visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, future plans, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. Contacts: Investors Jenny Kobin Remy Bernarda IR Advisory Solutions ir@opusgtx.com Media Kimberly Ha KKH Advisors 917-291-5744 kimberly.ha@kkhadvisors.com Source: Opus Genetics